Loading
Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer.
Oliver Sartor was co-principal investigator of VISION, which showed 177Lu-PSMA-617 improves survival in PSMA-positive metastatic castration-resistant prostate cancer and led to Pluvicto's approval, and was a lead investigator of PSMAfore, which moved the therapy before chemotherapy. He also co-led ALSYMPCA (radium-223). He directs the radiopharmaceutical trials programme at Mayo Clinic.
Shares PSMAfore, VISION, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Lutetium-177 vipivotide tetraxetan.
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters) and the tags prostate, radioligand.
Shares VISION, VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer, Lutetium-177 vipivotide tetraxetan, PSMA and the tag radioligand.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.